Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process

Vaccine

Volumn 28, Issue 30, 2010, Pages 4810-4816

  van de Waterbeemd, Bas ^a   Streefland, Mathieu ^a,b   van der Ley, Peter ^a   Zomer, Bert ^a   van Dijken, Harry ^a   Martens, Dirk ^b   Wijffels, René ^b   van der Pol, Leo ^a  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Aggregation; Immunogenicity; LpxL1; Neisseria meningitidis; OMV; Purification process; RmpM; Toxicity; Yield

Indexed keywords

BACTERIAL VACCINE; BACTERIUM LIPOPOLYSACCHARIDE; DETERGENT; EDETIC ACID; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 6; NEISSERIA MENINGITIDIS VACCINE; OUTER MEMBRANE VESICLE VACCINE; PORIN A; UNCLASSIFIED DRUG; LIPOPOLYSACCHARIDE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; CONTROLLED STUDY; CROSS PROTECTION; DRUG PURIFICATION; DRUG SAFETY; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOGENICITY; MACROPHAGE; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SUPERNATANT; TOXICITY TESTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MUTATION; TOXICITY;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; GENETIC ENGINEERING; LIPOPOLYSACCHARIDES; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; MUTATION; NEISSERIA MENINGITIDIS, SEROGROUP B;

EID: 77954216322     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.082     Document Type: Article

References (68)

1. Girard M.P., Preziosi M.P., Aguado M.T., Kieny M.P. A review of vaccine research and development: meningococcal disease. Vaccine 2006, 24(22):4692-4700.
2. Sharip A., Sorvillo F., Redelings M.D., Mascola L., Wise M., Nguyen D.M. Population-based analysis of meningococcal disease mortality in the United States: 1990-2002. Pediatr Infect Dis J 2006, 25(3):191-194.
3. Kaplan S.L., Schutze G.E., Leake J.A., Barson W.J., Halasa N.B., Byington C.L., et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006, 118(4):e979-e984.
4. Trotter C.L., Chandra M., Cano R., Larrauri A., Ramsay M.E., Brehony C., et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007, 31(1):27-36.
5. Gray S.J., Trotter C.L., Ramsay M.E., Guiver M., Fox A.J., Borrow R., et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006, 55(Pt 7):887-896.
6. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. Jama 2008, 299(2):173-184.
7. Morley S.L., Pollard A.J. Vaccine prevention of meningococcal disease, coming soon?. Vaccine 2001, 20(5-6):666-687.
8. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2(8346):355-357.
9. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338(8775):1093-1096.
10. Thornton V., Lennon D., Rasanathan K., O'Hallahan J., Oster P., Stewart J., et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006, 24(9):1395-1400.
11. Martin D.R., Walker S.J., Baker M.G., Lennon D.R. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998, 177(2):497-500.
12. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991, 14(2):195-207. discussion 208-10.
13. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Froholm L.O., et al. Production, characterization and control of MenB-vaccine " Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991, 14(2):67-79. discussion 79-80.
14. Deatherage B.L., Lara J.C., Bergsbaken T., Rassoulian Barrett S.L., Lara S., Cookson B.T. Biogenesis of bacterial membrane vesicles. Mol Microbiol 2009, 72(6):1395-1407.
15. Saukkonen K., Leinonen M., Abdillahi H., Poolman J.T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 1989, 7(4):325-328.
16. Martin D.R., Ruijne N., McCallum L., O'Hallahan J., Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006, 13(4):486-491.
17. van der Ley P., van der Biezen J., Poolman J.T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995, 13(4):401-407.
18. Claassen I., Meylis J., van der Ley P., Peeters C., Brons H., Robert J., et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996, 14(10):1001-1008.
19. de Kleijn E., van Eijndhoven L., Vermont C., Kuipers B., van Dijken H., Rumke H., et al. Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 2001, 20(3-4):352-358.
20. van den Dobbelsteen G.P., van Dijken H.H., Pillai S., van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 2007, 25(13):2491-2496.
21. Arigita C., Luijkx T., Jiskoot W., Poelen M., Hennink W.E., Crommelin D.J., et al. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives. Vaccine 2005, 23(43):5091-5098.
22. Arigita C., Kersten G.F., Hazendonk T., Hennink W.E., Crommelin D.J., Jiskoot W. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine 2003, 21(9-10):950-960.
23. Steeghs L., Tommassen J., Leusen J.H., van de Winkel J.G., van der Ley P. Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. J Endotoxin Res 2004, 10(2):113-119.
24. Koeberling O., Giuntini S., Seubert A., Granoff D.M. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 2009, 16(2):156-162.
25. Koeberling O., Seubert A., Granoff D.M. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 2008, 198(2):262-270.
26. van der Voort E.R., van der Ley P., van der Biezen J., George S., Tunnela O., van Dijken H., et al. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 1996, 64(7):2745-2751.
27. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl. 2):B3-B12.
28. Cametti C. Polyion-induced aggregation of oppositely charged liposomes and charged colloidal particles: the many facets of complex formation in low-density colloidal systems. Chem Phys Lipids 2008, 155(2):63-73.
29. Zollinger W.D., Mandrell R.E., Griffiss J.M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest 1979, 63(5):836-848.
30. Post D.M., Zhang D., Eastvold J.S., Teghanemt A., Gibson B.W., Weiss J.P. Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B. J Biol Chem 2005, 280(46):38383-38394.
31. Devoe I.W., Gilchrist J.E. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J Exp Med 1973, 138(5):1156-1167.
32. Hoekstra D., van der Laan J.W., de Leij L., Witholt B. Release of outer membrane fragments from normally growing Escherichia coli. Biochim Biophys Acta 1976, 455(3):889-899.
33. Guthrie T., Wong S.Y., Liang B., Hyland L., Hou S., Hoiby E.A., et al. Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis. Infect Immun 2004, 72(5):2528-2537.
34. Katial R.K., Brandt B.L., Moran E.E., Marks S., Agnello V., Zollinger W.D. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect Immun 2002, 70(2):702-707.
35. Saunders N.B., Shoemaker D.R., Brandt B.L., Moran E.E., Larsen T., Zollinger W.D. Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect Immun 1999, 67(1):113-119.
36. Drabick J.J., Brandt B.L., Moran E.E., Saunders N.B., Shoemaker D.R., Zollinger W.D. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 1999, 18(1-2):160-172.
37. Ferrari G., Garaguso I., Adu-Bobie J., Doro F., Taddei A.R., Biolchi A., et al. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 2006, 6(6):1856-1866.
38. van der Ley P., Steeghs L., Hamstra H.J., ten Hove J., Zomer B., van Alphen L. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 2001, 69(10):5981-5990.
39. Fisseha M., Chen P., Brandt B., Kijek T., Moran E., Zollinger W. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun 2005, 73(7):4070-4080.
40. Steeghs L., Kuipers B., Hamstra H.J., Kersten G., van Alphen L., van der Ley P. Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response. Infect Immun 1999, 67(10):4988-4993.
41. Fransen F., Boog C.J., van Putten J.P., van der Ley P. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect Immun 2007, 75(12):5939-5946.
42. Arigita C., Jiskoot W., Westdijk J., van Ingen C., Hennink W.E., Crommelin D.J., et al. Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines. Vaccine 2004, 22(5-6):629-642.
43. Klugman K.P., Gotschlich E.C., Blake M.S. Sequence of the structural gene (rmpM) for the class 4 outer membrane protein of Neisseria meningitidis, homology of the protein to gonococcal protein III and Escherichia coli OmpA, and construction of meningococcal strains that lack class 4 protein. Infect Immun 1989, 57(7):2066-2071.
44. Holten E. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol 1979, 9(2):186-188.
45. Jennings M.P., van der Ley P., Wilks K.E., Maskell D.J., Poolman J.T., Moxon E.R. Cloning and molecular analysis of the galE gene of Neisseria meningitidis and its role in lipopolysaccharide biosynthesis. Mol Microbiol 1993, 10(2):361-369.
46. Prachayasittikul V., Isarankura-Na-Ayudhya C., Tantimongcolwat T., Nantasenamat C., Galla H.J. EDTA-induced membrane fluidization and destabilization: biophysical studies on artificial lipid membranes. Acta Biochim Biophys Sin (Shanghai) 2007, 39(11):901-913.
47. Baart G.J., Willemsen M., Khatami E., de Haan A., Zomer B., Beuvery E.C., et al. Modeling Neisseria meningitidis B metabolism at different specific growth rates. Biotechnol Bioeng 2008, 101(5):1022-1035.
48. Lugtenberg B., Meijers J., Peters R., van der Hoek P., van Alphen L. Electrophoretic resolution of the " major outer membrane protein" of Escherichia coli K12 into four bands. FEBS Lett 1975, 58(1):254-258.
49. Baart G.J., de Jong G., Philippi M., van't Riet K., van der Pol L.A., Beuvery E.C., et al. Scale-up for bulk production of vaccine against meningococcal disease. Vaccine 2007, 25(34):6399-6408.
50. Gerhardt P., Murray R.G.E., Wood W.A., Krieg N.R. Methods for general and molecular bacteriology 1994, American Society for Microbiology, Washington DC.
51. Welch D.F. Applications of cellular fatty acid analysis. Clin Microbiol Rev 1991, 4(4):422-438.
52. Jantzen E., Bryn K., Bergan T., Bovre K. Gas chromatography of bacterial whole cell methanolysates; V. Fatty acid composition of Neisseriae and Moraxellae. Acta Pathol Microbiol Scand B: Microbiol Immunol 1974, 82(6):767-779.
53. Westphal O., Jann J.K. Bacterial lipopolysaccharide extraction with phenol-water and further application of the procedure. Methods Carbohydr Chem 1965, 5:83-91.
54. Luijkx T.A., van Dijken H., Hamstra H.J., Kuipers B., van der Ley P., van Alphen L., et al. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form. Infect Immun 2003, 71(11):6367-6371.
55. Geurtsen J., Steeghs L., Hamstra H.J., Ten Hove J., de Haan A., Kuipers B., et al. Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis. Infect Immun 2006, 74(10):5574-5585.
56. Ziegler-Heitbrock H.W., Thiel E., Futterer A., Herzog V., Wirtz A., Riethmuller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 1988, 41(3):456-461.
57. Grizot S., Buchanan S.K. Structure of the OmpA-like domain of RmpM from Neisseria meningitidis. Mol Microbiol 2004, 51(4):1027-1037.
58. Koebnik R. Proposal for a peptidoglycan-associating alpha-helical motif in the C-terminal regions of some bacterial cell-surface proteins. Mol Microbiol 1995, 16(6):1269-1270.
59. Prinz T., Tommassen J. Association of iron-regulated outer membrane proteins of Neisseria meningitidis with the RmpM (class 4) protein. FEMS Microbiol Lett 2000, 183(1):49-53.
60. Pridmore A.C., Wyllie D.H., Abdillahi F., Steeghs L., van der Ley P., Dower S.K., et al. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2. J Infect Dis 2001, 183(1):89-96.
61. Gaines Das R.E., Brugger P., Patel M., Mistry Y., Poole S. Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis. J Immunol Methods 2004, 288(1-2):165-177.
62. Luijkx T., van Dijken H., van Els C., van den Dobbelsteen G. Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine. Vaccine 2006, 24(10):1569-1577.
63. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003, 188(11):1730-1740.
64. Serruto D., Spadafina T., Ciucchi L., Lewis L.A., Ram S., Tontini M., et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 2010, 107(8):3770-3775.
65. Leive L. Release of lipopolysaccharide by EDTA treatment of E. coli. Biochem Biophys Res Commun 1965, 21(4):290-296.
66. ICH, Specifications (Q6B): Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ; 1999. http://www.ich.org/.
67. Sybachin A.V., Efimova A.A., Litmanovich E.A., Menger F.M., Yaroslavov A.A. Complexation of polycations to anionic liposomes: composition and structure of the interfacial complexes. Langmuir 2007, 23(20):10034-10039.
68. Yaroslavov A.A., Efimova A.A., Lobyshev V.I., Kabanov V.A. Reversibility of structural rearrangements in the negative vesicular membrane upon electrostatic adsorption/desorption of the polycation. Biochim Biophys Acta 2002, 1560(1-2):14-24.